GLP-1 and Liver Health: Semaglutide's MASH Approval Explained

Semaglutide's FDA approval for MASH (metabolic dysfunction-associated steatohepatitis) marks only the second drug ever approved for this condition — and it may be the more impactful one. Here's what the clinical evidence shows.

What Is MASH?

MASH is a progressive liver disease characterized by fat accumulation, inflammation, and fibrosis (scarring). It affects an estimated 5-12% of US adults and can progress to cirrhosis, liver failure, and hepatocellular carcinoma. Obesity is the primary risk factor. Until recently, the only treatment was lifestyle modification — weight loss, exercise, and dietary changes.

What Semaglutide Does for the Liver

Clinical trials demonstrated that semaglutide reduced liver inflammation and fibrosis in MASH patients. Researchers identified specific GLP-1 receptor-expressing cells in the liver that, when activated by semaglutide, initiate an anti-inflammatory signaling cascade. This represents a direct hepatoprotective effect beyond what weight loss alone would produce.

The Clinical Significance

For patients with both obesity and MASH, semaglutide now addresses the root cause (obesity), the liver-specific pathology (inflammation and fibrosis), and major downstream risks (cardiovascular disease, kidney disease). A single medication targeting multiple organ systems — this is the multi-system medicine paradigm that the 2026 Lancet review highlighted.